In France, the issue of plant-based treatments is progressing in stages, with a clear rationale: to open up possibilities for certain patients while maintaining a strict, medically supervised, and safe framework. Recent events confirm this approach with the temporary extension of the medical cannabis trial until March 31, 2026, for patients already enrolled. This development is of interest to patients, healthcare professionals, economic stakeholders in the hemp industry, and, more broadly, all those closely following the future of medical cannabis in France.
For adults learning about hemp-based products, it's essential to clearly distinguish between their uses. On the one hand, there's a very limited regulatory framework for cannabis-based medications intended for certain serious medical conditions; on the other, there's the CBD , which operates according to a different logic and should never be confused with driving under the influence of drugs, which is strictly prohibited. Between therapeutic hopes, commercial opportunities, and road safety requirements, the subject deserves a thorough and comprehensive analysis.
Extended access, but always very strictly controlled
The trial of cannabis for therapeutic use began on March 26, 2021. It was designed from the outset as a controlled program, reserved for specific medical situations and closely monitored by health authorities. It is therefore not a general legalization, but an exceptional framework intended to observe, secure, and evaluate certain prescriptions.
Since March 27, 2024, no new patients have been admitted to this program. However, patients already enrolled and still receiving treatment continue to be cared for thanks to an exceptional transitional extension until March 31, 2026. This decision avoids disruptions in care for individuals often suffering from serious illnesses, while also allowing the authorities time to finalize the future framework.
The ministry also indicated that the regulations defining the production and authorization of cannabis for medical use have been submitted to the European Commission. This is an important regulatory step, as it demonstrates that France is not ruling out regulated and secure access. For industry observers, this signal confirms that progress is being made, even if the timeline remains cautious.
Which patients are affected today?
The current system targets patients with serious illnesses, within a limited framework and with specific monitoring. Prescriptions are therefore not intended for recreational use or for general public requests. This refers to situations where medical teams assess the potential benefit of the treatment in a highly supervised environment.
Patients included in the study are informed of precautions for use, possible side effects, and contraindications. This information is essential because plant-based treatments are not, by nature, harmless. As with any medication, the benefit-risk balance must be carefully assessed, with clear guidelines on dosage, monitoring, and adherence.
For those seeking practical information, Service-Public directs users to an official search tool for participating organizations, provided by the ANSM (French National Agency for Medicines and Health Products Safety). This helps avoid misleading information, vague promises, or inappropriate channels. In such a sensitive area, the best course of action is always to use institutional and medical channels.
A transitional phase that protects the continuity of care
The extension until March 31, 2026, does not signify a large-scale reopening, but it provides significant security for patients already enrolled in the program. When treatment is underway and part of a comprehensive medical strategy, its abrupt interruption can be a real source of anxiety. Continuity of care is therefore as much a human issue as a health one.
Another practical point: the purchase of cannabis-based medications authorized for use in the trial will continue to be reimbursed by the national health insurance system during this transitional phase, at the latest until March 31, 2026. For patients who are often vulnerable, this financial aspect is far from negligible. It helps to limit the financial burden and prevents access from depending solely on personal budget.
This temporary coverage also underscores a fundamental principle: when a treatment enters a supervised therapeutic pathway, it cannot be managed like a simple consumer product. The role of insurance, the doctor, and the pharmacy is rooted in a public health approach, with essential safeguards in place.
What this means for retailers and the industry
For retailers specializing in wellness hemp, this news is generating interest, but it also necessitates education. In France, medical cannabis falls under a specific medical framework, distinct from the sale of legal CBD, oils, flowers, resins, or next-generation cannabinoids that comply with current regulations. Mixing these two categories would be a mistake for both consumers and professionals.
However, regulatory developments show that a French production sector is being prepared for the long term. As early as 2022, the work of the ANSM (French National Agency for Medicines and Health Products Safety) revealed discussions on structuring a medical cannabis supply chain in France, including economic operators and a framework for cultivation authorization. For the sector, this is a strategic signal: traceability, compliance, quality control, and standardization will become even more crucial.
Reputable brands therefore have every reason to strengthen their responsible messaging: explaining the difference between wellness and medical uses, highlighting laboratory analyses, reminding customers of legal limits, and directing them to the appropriate contacts when a health question arises. In the medium term, this clarity can boost public trust and further professionalize the entire hemp ecosystem.
A still modest but structuring experiment
Seven months after the launch of the trial, the Ministry of Health indicated that approximately 1,000 patients had been enrolled, with over 1,000 healthcare professionals involved. Nationally, this number remains limited. However, for a trial, it already represents a valuable working basis for better understanding the conditions of use, patient profiles, and follow-up constraints.
These figures also show that the issue is no longer theoretical. Doctors, pharmacists, and hospital facilities have actively participated in the program. This allows for the development of on-the-ground expertise, essential before any potential widespread implementation. When it comes to sensitive treatments, practical experience is just as important as the regulations themselves.
For patients and market observers, this structuring aspect is important. Even if access remains limited, the trial will have helped to lay the groundwork: training, protocols, logistics, pharmacovigilance, and coordination between stakeholders. This is often how sustainable frameworks are built, step by step, without rushing beyond the necessary safety guarantees.
Road safety: a non-negotiable point of vigilance
On the road, the message from authorities is unambiguous: driving under the influence of drugs is prohibited in France and constitutes a criminal offense. The ONISR (National Interministerial Road Safety Observatory) consistently reiterates this principle, and it remains essential to emphasize it in all content relating to hemp or cannabis products. Regardless of societal perceptions of the issue, the rules of the road remain strictly enforced.
The criminal penalty for driving under the influence of drugs automatically results in a 6-point deduction from the driver's license. Refusal to submit to tests, whether saliva or blood, can be punished in the same way as driving under the influence of drugs itself. In other words, roadside checks are not a mere administrative detail: they are part of a firm policy of prevention and enforcement.
In a context where the ONISR (National Interministerial Road Safety Observatory) recorded 1,050,369 offenses in 2024, a 9.5% increase year-on-year, it is understandable that risky behaviors are receiving increased attention. The final 2025 results for the main road accident indicators are now available, demonstrating that statistical monitoring remains very active. For adult users, the rule is simple: never drive after using substances that may impair your abilities.
Cannabis, medication and driving: risks that are still underestimated
The French Road Safety Authority emphasizes that the negative effects of cannabis on driving remain largely unknown, or even ignored. This is a crucial point, as many people underestimate the potential impact on attention, reaction time, and perception. The danger is all the greater because certain forms of cannabis use have become commonplace in the public imagination.
Authorities also remind the public that taking medication with alcohol and/or drugs, particularly cannabis, significantly increases the risk of accidents. This reminder must be taken very seriously in the context of medical treatment. A patient may be following a legitimate therapeutic protocol and still need to refrain from driving depending on their individual circumstances, medical recommendations, and the effects they experience.
The ActuSAM study, reported by the ONISR (National Inter-ministerial Road Safety Observatory), highlights an average attributable risk of 17.8, with a marked dose-response effect depending on the amount of alcohol consumed. The message is clear: combined consumption is particularly dangerous. For responsible retailers and news outlets alike, it is essential to emphasize this point without ambiguity or minimization.
The signal from accident statistics must be taken seriously
The 2024 report on road traffic offenses published by the ONISR (National Interministerial Road Safety Observatory) mentions the presence of cannabis alone detected in a significant proportion of the cases analyzed in fatal accidents. While statistics must always be interpreted rigorously, this signal is worrying. It serves as a reminder that the issue is not only legal, but deeply linked to the protection of lives.
In the public debate, some may be tempted to conflate regulated therapeutic use, cannabis consumption, and hemp-based wellness products. However, from a road safety perspective, the reasoning must remain extremely concrete: what matters is the risk of impaired ability and the exposure of other road users. Caution is not a slogan; it is a necessity.
This reality demands mature communication from the entire industry. Providing information about products is essential; trivializing their use before driving is not. The more professional the market becomes, the higher the demand for responsible information must rise. This is also how reputable players distinguish themselves in the long term.
The evolution of medical cannabis in France demonstrates that regulated access to treatments derived from the plant is possible, but only within a precise, limited, and highly secure framework. The extension until March 31, 2026, protects patients already enrolled, while the notification of the legislation to the European Commission suggests a future, more stable organization of production and authorization. For the patients concerned, this is a sign of continuity; for healthcare professionals, a sign of preparedness.
For retailers of legal hemp and CBD, the challenge is clear: to inform without confusing, to support without making unrealistic promises, and to constantly remind consumers of safety rules, especially on the road. The future of the industry depends on quality, compliance, and education. And on one point, there must be no gray areas: whether for medical use or not, road safety remains an absolute priority.
